1. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models

   • Yong S. Chang
   • Jalila Adnane
   • Scott Wilhelm

   Original Article 08 December 2006 Pages: 561 - 574

   

2. Pharmacokinetics of low-dose nedaplatin and validation of AUC prediction in patients with non-small-cell lung carcinoma

   • Takenori Niioka
   • Tsukasa Uno
   • Tomonori Tateishi

   Original Article 16 August 2006 Pages: 575 - 580

   

3. Phase I study of weekly DN-101, a new formulation of calcitriol, in patients with cancer

   • Tomasz M. Beer
   • Milind M. Javle
   • Donald L. Trump

   Original Article 26 October 2006 Pages: 581 - 587

4. In vitro anti-cancer activity and structure–activity relationships of natural products isolated from fruits of Panax ginseng

   • Wei Wang
   • Yuqing Zhao
   • Ruiwen Zhang

   Original Article 22 August 2006 Pages: 589 - 601

   

5. Role of nitric oxide on pathogenesis of 5-fluorouracil induced experimental oral mucositis in hamster

   • R. F. C. Leitão
   • R. A. Ribeiro
   • G. A. C. Brito

   Original Article 31 August 2006 Pages: 603 - 612

   

6. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study

   • Daniele Santini
   • Bruno Vincenzi
   • Giuseppe Tonini

   Original Article 31 August 2006 Pages: 613 - 620

   

7. Gemcitabine and vinorelbine in recurrent advanced non-small cell lung cancer: sequence does matter

   • Rosalyn Juergens
   • Julie Brahmer
   • David Ettinger

   Original Article 26 August 2006 Pages: 621 - 629

8. A phase I study of paclitaxel, cisplatin, and fluorouracil (TCF) for advanced gastric cancer

   • Takuo Hara
   • Kenji Omura
   • Junichi Sakamoto

   Original Article 22 August 2006 Pages: 631 - 636

9. Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?

   • Emilio Bajetta
   • Laura Catena
   • Roberto Bajetta

   Original Article 26 August 2006 Pages: 637 - 642

   

10. Histological changes in bladders of patients submitted to ifosfamide chemotherapy even with mesna prophylaxis

    • Marcos Venício Alves Lima
    • Francisco Valdeci Ferreira
    • Ronaldo Albuquerque Ribeiro

    Original Article 01 September 2006 Pages: 643 - 650

    

11. Antitumor activity of HER1/EGFR tyrosine kinase inhibitor erlotinib, alone and in combination with CPT-11 (irinotecan) in human colorectal cancer xenograft models

    • Jianping Chen
    • Melissa Smith
    • Brian Higgins

    Original Article 26 August 2006 Pages: 651 - 659

    

12. Antitumour action of 5,6-dimethylxanthenone-4-acetic acid in rats bearing chemically induced primary mammary tumours

    • Johnson J. Liu
    • Lai-Ming Ching
    • Mark J. McKeage

    Original Article 31 August 2006 Pages: 661 - 669

    

13. Pharmacodynamic and toxicokinetic evaluation of the novel MEK inhibitor, PD0325901, in the rat following oral and intravenous administration

    • Alan P. Brown
    • Tage C. G. Carlson
    • Michael J. Graziano

    Original Article 31 August 2006 Pages: 671 - 679

    

14. Pharmacokinetics of 5,6-dimethylxanthenone-4-acetic acid (AS1404), a novel vascular disrupting agent, in phase I clinical trial

    • M. B. Jameson
    • B. C. Baguley
    • on behalf of the Cancer Research (UK) Phase I/II Trials Committee

    Clinical Trial Report 23 September 2006 Pages: 681 - 687

    

15. Phase I dose-escalation study of a novel antitumor agent, SR271425, administered intravenously in split doses (d1–d2–d3) in patients with refractory solid tumors

    • M. Campone
    • N. Isambert
    • P. Fumoleau

    Clinical Trial Report 10 October 2006 Pages: 689 - 695

    

16. Dihydrodiol dehydrogenase in drug resistance and sensitivity of human carcinomas

    • Bih Fang Pan
    • J. Arly Nelson

    Short Communication 29 September 2006 Pages: 697 - 702